Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Selective Cytopheretic Device (SCD) treatments will improve survival in patients testing positive for COVID-19 infection diagnosed with Acute Kidney Injury (AKI) or ARDS.
Description: All cause mortality at Day 60
Measure: Mortality at Day 60 Time: 60 days post treatmentDescription: Dialysis Dependency at Day 60
Measure: Dialysis Dependency Time: 60 days post treatmentDescription: Ventilation free survival at Day 28
Measure: Ventilation at Day 28 Time: 28 days post treatmentDescription: Dialysis Dependency at Day 28
Measure: Dialysis Dependency Time: 28 days post treatmentDescription: All cause mortality at Day 28
Measure: Mortality at Day 28 Time: 28 days post treatmentDescription: Change from baseline in urine output
Measure: Urinary output change Time: 10 days of treatmentDescription: Change from baseline in PO2/FiO2
Measure: P02/FiO2 change Time: 10 days of treatmentDescription: Assessment of SAEs, AE and UADEs
Measure: Safety Assessments Time: 10 days of treatmentDescription: Assessment of device performance
Measure: SCD Integrity Time: 10 days of treatment